ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 380,74
0,92%
Dow Jones
42 721,33
0,35%
DAX
19 909,14
-0,25%
Brent Oil
74,395
0,40%
Bitcoin
95 495,82
3,06%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Relmada Therapeutics Inc (RLMD) Cours

Relmada Therapeutics Inc

Relmada Therapeutics Inc (RLMD)

NASDAQ
0,44
-0,019
( -4,14% )
Mis à jour : 15:43:05
Retardé de 15 minutes

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Statistiques et détails clés

Dernier
0,44
Prix Achat
0,4401
Prix Vente
0,467
Volume échangé
334 365
0,4354 Fourchette du Jour 0,4805
0,3416 Plage de 52 semaines 7,2225
Cap du marché
13,277M
Clôture Veille
0,459
Ouverture
0,4801
Dernière Transaction
1
@
0.4535
Dernière heure de transaction
15:43:00
Volume financier
US$ 155 967
VWAP
0,466458
Volume moyen (3 m)
905 063
Actions en circulation
30 174 202
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-0,14
Bénéfice par action (BPA)
-3,27
Chiffre d'affairess
-
Bénéfice net
-98,79M

À propos de Relmada Therapeutics Inc

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmet... Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications. Show more

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Site Web
www.relmada.com
Siège social
Reno, Nevada, USA
Fondé
-
Relmada Therapeutics Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker RLMD. Le dernier cours de clôture d'Relmada Therapeutics était de US$0,46. Au cours de la dernière année, les actions de Relmada Therapeutics ont été négociées dans une fourchette de prix de US$ 0,3416 à US$ 7,2225.

Relmada Therapeutics compte actuellement 30 174 202 actions en circulation. La capitalisation boursière d'Relmada Therapeutics est de US$13,85 million. Relmada Therapeutics a un ratio cours/bénéfice (ratio PE) de -0.14.

RLMD Dernières nouvelles

Plus de nouvelles

Form 8-K - Current report

09 Décembre 2024
Edgar (US Regulatory)

Form 8-K - Current report

04 Décembre 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

14 Novembre 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

07 Novembre 2024
Edgar (US Regulatory)

Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm PR Newswire NEW YORK, Sept. 16, 2024 NEW YORK, Sept. 16, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder...

17 Septembre 2024
PR Newswire (US)

Form EFFECT - Notice of Effectiveness

13 Septembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

11 Septembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

11 Septembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

11 Septembre 2024
Edgar (US Regulatory)

Form S-3 - Registration statement under Securities Act of 1933

30 Août 2024
Edgar (US Regulatory)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10.0822.22222222220.360.49220.34313777040.42509381CS
4-2.81-86.46153846153.253.250.341625402160.51032017CS
12-3.06-87.42857142863.53.980.34169050630.77366806CS
26-2.59-85.47854785483.034.470.34165164681.25552262CS
52-3.8-89.62264150944.247.22250.34163582222.07048075CS
156-21.18-97.964847363621.6238.680.34163755238.16007426CS
260-37.62-98.843930635838.06540.341627802013.13953231CS

RLMD - Frequently Asked Questions (FAQ)

What is the current Relmada Therapeutics share price?
The current share price of Relmada Therapeutics is US$ 0,44
How many Relmada Therapeutics shares are in issue?
Relmada Therapeutics has 30 174 202 shares in issue
What is the market cap of Relmada Therapeutics?
The market capitalisation of Relmada Therapeutics is USD 13,85M
What is the 1 year trading range for Relmada Therapeutics share price?
Relmada Therapeutics has traded in the range of US$ 0,3416 to US$ 7,2225 during the past year
What is the PE ratio of Relmada Therapeutics?
The price to earnings ratio of Relmada Therapeutics is -0,14
What is the reporting currency for Relmada Therapeutics?
Relmada Therapeutics reports financial results in USD
What is the latest annual profit for Relmada Therapeutics?
The latest annual profit of Relmada Therapeutics is USD -98,79M
What is the registered address of Relmada Therapeutics?
The registered address for Relmada Therapeutics is 50 WEST LIBERTY STREET SUITE 880, RENO, NEVADA, 89501
What is the Relmada Therapeutics website address?
The website address for Relmada Therapeutics is www.relmada.com
Which industry sector does Relmada Therapeutics operate in?
Relmada Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
APMAptorum Group Ltd
US$ 5,8151
(329,16%)
41,17M
ONCOOnconetix Inc
US$ 1,23
(181,46%)
76,68M
VRMEVerifyMe Inc
US$ 1,6587
(109,99%)
41,09M
BDMDBaird Medical Investment Holdings Ltd
US$ 2,11
(100,95%)
220,75k
FLYEFly E Group Inc
US$ 1,14
(70,15%)
21,41M
SGMOSangamo Therapeutics Inc
US$ 1,0903
(-53,41%)
4,99M
COCPCocrystal Pharma Inc
US$ 2,14
(-34,15%)
116,32k
WATTEnergous Corporation
US$ 1,75
(-33,96%)
9,43M
INTZIntrusion Inc
US$ 4,1476
(-26,98%)
3,95M
MSTXTidal Trust II Defiance Daily Target 2x Long MSTR ETF
US$ 41,39
(-21,94%)
2,73M
EYENEyenovia Inc
US$ 0,176
(55,34%)
164,44M
CRKNCrown Electrokinetics Corporation
US$ 0,2129
(53,50%)
150,84M
SVMHSRIVARU Holding Ltd
US$ 0,0496
(48,50%)
117,55M
BHATBlue Hat Interactive Entertainment Technology
US$ 0,1899
(53,64%)
98,91M
XTIAXTI Aerospace Inc
US$ 0,0454
(14,94%)
93,3M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
RLMD
Relmada Therapeutics
AQSE
FGQI.GB
FIL Fund Management Irel...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés